Tezacaftor
Vanzacaftor, tezacaftor, deutivacaftor safe in children with cystic fibrosis
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally tolerated it well, according to data published in The Lancet Respiratory Medicine.
Vanzacaftor, tezacaftor, deutivacaftor similar to current cystic fibrosis standard of care
Among individuals aged at least 12 years with cystic fibrosis, receipt of vanzacaftor/tezacaftor/deutivacaftor was similar or better than Trikafta depending on the endpoint, according to results published in The Lancet Respiratory Medicine.
Neuropsychological side effects remain 6 months into cystic fibrosis triple therapy
At three follow-up visits within 6 months, reports of neuropsychological side effects rose or stayed stable among patients with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor therapy, according to results published in CHEST.
FDA approves Alyftrek for cystic fibrosis treatment
The FDA has approved Alyftrek for patients aged 6 years and older with cystic fibrosis with certain mutations, according to a press release from Vertex Pharmaceuticals.
Cystic fibrosis triple therapy improves clinical outcomes in N1303K mutation
Percent-predicted FEV1 and respiratory-related quality of life improved with 28-day triple therapy in individuals with the N1303K cystic fibrosis transmembrane conductance defect, according to data published in Lancet Respiratory Medicine.
Cystic fibrosis triple therapy outcomes improve regardless of prior modulators
BOSTON — Having vs. not having past cystic fibrosis transmembrane conductance regulator modulator exposure did not change positive outcomes seen with elexacaftor/tezacaftor/ivacaftor, according to data presented at the CHEST Annual Meeting.
Cystic fibrosis triple therapy improves lung ventilation, morphology in children
Lung clearance index and MRI scores improved in kids aged 6 to 11 years with cystic fibrosis and at least one F508del allele receiving elexacaftor/tezacaftor/ivacaftor therapy, according to results published in European Respiratory Journal.
Cystic fibrosis triple therapy does not eliminate bacterial infection predisposal in vitro
It is known that persons with cystic fibrosis are more susceptible to infections; however, the impact of elexacaftor/tezacaftor/ivacaftor therapy on this susceptibility has not been well studied yet.
Triple therapy improves chronic rhinosinusitis outcomes in cystic fibrosis
Patients with cystic fibrosis had improved chronic rhinosinusitis outcomes after 1 year of elexacaftor/tezacaftor/ivacaftor therapy, according to results published in JAMA Otolaryngology-Head & Neck Surgery.
Cystic fibrosis triple therapy safe, tolerable for 144 weeks in older children
Elexacaftor/tezacaftor/ivacaftor appeared safe and well tolerated among kids aged 12 years and older with cystic fibrosis and either F508del/minimal function or F508del/F508del genotypes for up to 144 weeks, according to study results.